Why did MEM.AX stock jump today?

MEM.AX stock rose **40.00%** intraday on heavy volume as traders reacted to renewed interest in Memphasys’ IVF device pipeline and stronger biotech sector flows. There is no formal earnings report today; volume suggests momentum trading rather than confirmed corporate news.

What is the Meyka AI forecast for MEM.AX stock?

Meyka AI's forecast model projects a monthly price of **A$0.010** for MEM.AX stock, implying about **42.86%** upside from **A$0.007**. The model also shows a year projection of **A$0.00287**. Forecasts are projections, not guarantees.

What are the main risks for MEM.AX stock?

Key risks for MEM.AX stock include low liquidity, negative operating cash flow, a weak current ratio (**0.25**), and reliance on product commercialisation or licensing catalysts. Funding and trial setbacks could trigger sharp downside moves.

What price targets should traders watch for MEM.AX stock?

Near-term technical resistance is at **A$0.011** (year high). Conservative targets are **A$0.012** (bull) and **A$0.004** (bear). Monitor whether MEM.AX stock holds above **A$0.006** on follow-through volume.

AU Stocks

MEM.AX up 40% intraday on ASX 03 Feb 2026: watch A$0.01 forecast upside

ByHuzaifa Zahoor February 3, 2026February 3, 2026

Memphasys Limited (MEM.AX stock) leads small-cap gainers intraday on ASX, trading up 40.00% to A$0.007 on 03 Feb 2026. Volume is heavy at 11,636,947.00 shares versus an average of 4,423,749.00, signalling speculative interest. The jump follows renewed attention to Memphasys’ fertility device pipeline and micro-cap positioning within the Australian biotechnology sector. We examine the drivers, valuation signals and short-term technical targets to explain why MEM.AX stock is a top gainer and what investors should watch next.